G G Zhanel


Affiliation: University of Manitoba
Country: Canada


  1. Domalaon R, Idowu T, Zhanel G, Schweizer F. Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?. Clin Microbiol Rev. 2018;31: pubmed publisher
    ..Antibiotic hybrids indeed have a promising future as a therapeutic strategy to overcome drug resistance in Gram-negative pathogens and/or expand the usefulness of our current antibiotic arsenal. ..
  2. Zhanel G, Golden A, Zelenitsky S, Wiebe K, Lawrence C, Adam H, et al. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs. 2019;79:271-289 pubmed publisher
    ..A distinguishing feature of cefiderocol is its activity against resistant P. aeruginosa, A. baumannii, S. maltophilia and Burkholderia cepacia. ..
  3. Karlowsky J, Adam H, Baxter M, Denisuik A, Lagacé Wiens P, Walkty A, et al. In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli. Antimicrob Agents Chemother. 2019;63: pubmed publisher
    ..25 µg/ml. The in vitro activity of sulopenem was unaffected by nonsusceptibility to trimethoprim-sulfamethoxazole and/or ciprofloxacin, multidrug-resistant phenotypes, extended-spectrum β-lactamases, or AmpC β-lactamases. ..
  4. Zhanel G, Baudry P, Tailor F, Cox L, Hoban D, Karlowsky J. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapene. J Antimicrob Chemother. 2009;64:824-8 pubmed publisher
    ..coli harbouring ESBLs, AmpC beta-lactamases and CRS when simulating clinically achievable serum concentrations, and represents a potential therapy for infections caused by these isolates. ..
  5. Yang X, Domalaon R, Lyu Y, Zhanel G, Schweizer F. Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa. J Clin Med. 2018;7: pubmed publisher
    ..aeruginosa. These synergistic combinations warrant further studies as there is an urgent need to develop new strategies to treat drug-resistant P. aeruginosa infections. ..
  6. request reprint
    Zhanel G, Johanson C, Embil J, Noreddin A, Gin A, Vercaigne L, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther. 2005;3:23-39 pubmed
    ..Ertapenem is a promising new carbapenem with excellent efficacy and safety for the treatment of a variety of community-acquired infections. It also appears to be of great value as an outpatient parenteral antimicrobial therapy. ..
  7. Zhanel G, Sniezek G, Schweizer F, Zelenitsky S, Lagacé Wiens P, Rubinstein E, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009;69:809-31 pubmed publisher
    ..Further clinical studies are needed to determine the efficacy and safety of ceftaroline, and to define its role in patient care. ..
  8. Denisuik A, Karlowsky J, Denisuik T, Nichols W, Keating T, Adam H, et al. In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitals. Antimicrob Agents Chemother. 2015;59:3623-6 pubmed publisher
    ..5 μg/ml (MIC, ≤8 μg/ml for 100% of isolates) and 16 μg/ml (MIC, ≤8 μg/ml for 87.8% of isolates) against gentamicin-nonsusceptible Enterobacteriaceae and P. aeruginosa isolates, respectively. ..
  9. Zhanel G, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Drugs. 2015;75:253-70 pubmed publisher
    ..Tedizolid is currently undergoing additional Phase III clinical trials for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilated nosocomial pneumonia (VNP). ..

More Information


  1. Zhanel G, Trapp S, Gin A, DeCorby M, Lagacé Wiens P, Rubinstein E, et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther. 2008;6:67-81 pubmed publisher
    ..Both telavancin and dalbavancin show promise as alternative treatments for patients with serious infections caused by resistant Gram-positive pathogens. ..
  2. request reprint
    Zhanel G, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban D, et al. Comparative review of the carbapenems. Drugs. 2007;67:1027-52 pubmed
    ..aeruginosa than meropenem. Clinical trials are required to establish the efficacy and safety of doripenem in moderate to severe infections, including nosocomial infections. ..
  3. request reprint
    Zhanel G, Wang X, Nichol K, Nikulin A, Wierzbowski A, Mulvey M, et al. Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004. Int J Antimicrob Agents. 2006;28:465-71 pubmed
    ..In conclusion, paediatric MDR S. pneumoniae simultaneously resistant to penicillin, erythromycin and T/S are genetically similar and disseminating across Canada. Prevnar provides excellent coverage of paediatric MDR S. pneumoniae. ..
  4. Zhanel G, Rossnagel E, Nichol K, Cox L, Karlowsky J, Zelenitsky S, et al. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. a. J Antimicrob Chemother. 2011;66:1301-5 pubmed publisher
    ..Ceftaroline ƒT(> MIC) of ? 92% (ceftaroline MICs, ? 1 mg/L) was bactericidal (? 3 log?? killing) against MSSA, CA-MRSA, HA-MRSA, hVISA, VISA and VRSA at 12 and 24 h. ..
  5. Karlowsky J, Adam H, Kosowan T, Baxter M, Nichol K, Laing N, et al. PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study. Diagn Microbiol Infect Dis. 2018;91:105-111 pubmed publisher
    ..5 ?g/mL; lowest maximum MIC, 2 ?g/mL) of eight antimicrobial agents tested and was the most active agent against each of the five commonest ribotypes (MIC90, 0.25-1 ?g/mL). ..
  6. request reprint
    Zhanel G, Hartel E, Adam H, Zelenitsky S, Zhanel M, Golden A, et al. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs. 2016;76:1737-1757 pubmed
    ..Overall, the in vitro activity, clinical efficacy, tolerability, and safety profile of solithromycin demonstrated to date suggest that it continues to be a promising treatment for CABP. ..
  7. Zhanel G, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/tazobactam: a novel cephalosporin/?-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31-51 pubmed publisher
    ..aeruginosa infections with this agent. Currently, ceftolozane/tazobactam is being evaluated in three phase III trials for the treatment of cUTI, cIAI, and VABP. ..
  8. request reprint
    Zhanel G, Karlowsky J, Schwartz B, Jensen S, Hoban D. Mecillinam activity compared to ampicillin, trimethoprim/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli. Chemotherapy. 1998;44:391-6 pubmed
    ..9% of ampicillin-resistant E. coli and 95.9% of trimethoprim/sulfamethoxazole-resistant E. coli. We conclude that mecillinam should be reevaluated for potential use in the treatment of community-acquired urinary tract infections. ..
  9. Zhanel G, Baxter M, Adam H, Sutcliffe J, Karlowsky J. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis. 2018;91:55-62 pubmed publisher
    ..Eravacycline demonstrates promising activity against recent clinical Gram-negative and Gram-positive bacteria, including multidrug-resistant pathogens. ..
  10. Zhanel G, Parkinson K, Higgins S, Denisuik A, Adam H, Pitout J, et al. Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus Escherichia coli using an in vitro model. Diagn Microbiol Infect Dis. 2017;88:271-275 pubmed publisher
    ..Our data help to explain the high (>90%) microbiological and clinical cure rates achieved with fosfomycin when used as a single 3-g oral dose to treat patients with acute uncomplicated cystitis. ..
  11. Karlowsky J, Walkty A, Baxter M, Arhin F, Moeck G, Adam H, et al. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. Diagn Microbiol Infect Dis. 2017;87:349-356 pubmed publisher
    ..06, 0.06, 0.06, respectively) and 144 isolates of MRSA (0.12, 0.06, 0.06, respectively) collected in 2015. ..
  12. Zhanel G, Karlowsky J. Kisameet Clay Isolated from the Central Coast of British Columbia, Canada, Demonstrates Broad-Spectrum Antimicrobial Activity. MBio. 2016;7:e00169 pubmed publisher
  13. Zhanel G, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs. 2016;76:567-88 pubmed publisher
    ..Eravacycline is a promising intravenous and oral fluorocycline that may offer an alternative treatment option for patients with serious infections, particularly those caused by multidrug-resistant Gram-negative pathogens. ..
  14. Zhanel G, Adam H, Low D, Blondeau J, Decorby M, Karlowsky J, et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011;69:291-306 pubmed publisher
  15. Zhanel G, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé Wiens P, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70:859-86 pubmed publisher
  16. Zhanel G, Johanson C, Laing N, Hisanaga T, Wierzbowski A, Hoban D. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary. Antimicrob Agents Chemother. 2005;49:1943-8 pubmed
    ..In conclusion, free-telithromycin concentrations in serum and ELF simulating C(max)/MIC > or = 3.5 and AUC(0-24 h)/MIC > or = 25 completely eradicated (> or =4 log(10) killing) macrolide-resistant S. pneumoniae at 24 and 48 h. ..
  17. Zhanel G, Karlowsky J, Harding G, Carrie A, Mazzulli T, Low D, et al. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother. 2000;44:1089-92 pubmed
    ..0, 18.9, 7.4, 0.1, and 1.2%, respectively. The majority of E. coli isolates resistant to ampicillin, trimethoprim-sulfamethoxazole, or ciprofloxacin were susceptible (MIC, <16 microg/ml) to mecillinam. ..
  18. Zhanel G, Schweizer F, Karlowsky J. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54 Suppl 3:S214-9 pubmed publisher
  19. Zhanel G, Decorby M, Adam H, Mulvey M, McCracken M, Lagacé Wiens P, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother. 2010;54:4684-93 pubmed publisher
    ..The prevalence of MRSA was 27.0% (of which genotypically 27.6% were CA-MRSA), while ESBL-producing E. coli occurred in 4.9% of isolates. An MDR phenotype was common in P. aeruginosa. ..
  20. request reprint
    Zhanel G, Karlowsky J, Rubinstein E, Hoban D. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther. 2006;4:9-25 pubmed
    ..e., nausea, vomiting and diarrhea) the most commonly reported. Tigecycline is a promising new broad-spectrum parenteral monotherapy for the treatment of patients with Gram-positive and -negative bacterial infections. ..
  21. Zhanel G, Lawrence C, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. 2018;78:65-98 pubmed publisher
    ..Finally, increased activity of imipenem-relebactam against P. aeruginosa may be of clinical benefit to patients with suspected or documented P. aeruginosa infections. ..
  22. Zhanel G, DeCorby M, Nichol K, Wierzbowski A, Baudry P, Karlowsky J, et al. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis. 2008;62:67-80 pubmed publisher
    ..aeruginosa), respectively...
  23. Zhanel G, Karlowsky J, Harding G, Balko T, Zelenitsky S, Friesen M, et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 1997;41:863-5 pubmed
    ..12 microg/ml) (n = 10), and was inactive against C. neoformans (MIC90, >10.24 microg/ml) (n = 15) and B. dermatitidis (MIC90, 16 microg/ml) (n = 29)...